Trial Profile

Phase I/II Study of Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 25 Jun 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Carboplatin; Docetaxel
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

20 Jun 2019 Status changed from active, no longer recruiting to discontinued.
26 Jan 2017 Planned End Date changed from 1 Aug 2016 to 1 Aug 2017.
22 Sep 2015 Planned End Date changed from 1 Aug 2014 to 1 Aug 2016 as reported in ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com